Tandem Diabetes Care Financial Statements
NASDAQ: TNDMHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tandem Diabetes Care revenue and earnings
In fiscal 2025, Tandem Diabetes Care generated $1.01 billion in revenue, up 7.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Tandem Diabetes Care reported a net loss of $204.7 million, compared with a loss of $96.0 million a year earlier. Gross margin was 53.8% (up from 52.1%) and operating margin -18.5%.
Diluted earnings per share came in at -$3.04. Over the last 5 fiscal years, TNDM's revenue has grown at a 15.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Tandem Diabetes Care income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.01B | 940.20M | 747.72M | 801.22M | 702.80M | 498.83M | 362.31M | 183.87M | 107.60M | 84.25M |
| Revenue growth (YoY) | +7.93% | +25.74% | -6.68% | +14.00% | +40.89% | +37.68% | +97.05% | +70.88% | +27.72% | +15.65% |
| Cost of Revenue | 468.72M | 450.63M | 380.03M | 388.23M | 326.58M | 238.31M | 168.09M | 94.04M | 63.51M | 60.66M |
| Gross Profit | 546.01M | 489.57M | 367.69M | 412.99M | 376.21M | 260.52M | 194.21M | 89.82M | 44.09M | 23.59M |
| Operating Expenses | 733.27M | 588.70M | 600.92M | 505.83M | 353.56M | 268.48M | 210.93M | 134.45M | 107.04M | 101.64M |
| Research & Development | 193.11M | 198.88M | 169.67M | 139.11M | 92.05M | 63.57M | 45.20M | 29.23M | 20.66M | 18.81M |
| Selling, General & Admin | 444.99M | 389.82M | 352.50M | 335.68M | 261.51M | 204.90M | 165.74M | 105.23M | 86.38M | 82.83M |
| Operating Income | -187.26M | -99.13M | -233.23M | -92.85M | 22.65M | -7.96M | -16.72M | -44.63M | -62.94M | -78.05M |
| Interest Expense | 7.91M | 7.42M | 9.88M | 6.21M | — | — | — | — | — | — |
| Other Income (Expense) | -13.02M | 7.26M | 12.98M | -4.00K | -6.75M | -28.32M | -7.88M | -77.93M | -10.08M | -5.41M |
| Pretax Income | -200.27M | -91.87M | -220.25M | -92.85M | 15.90M | -36.28M | -24.60M | -122.56M | -73.03M | -83.46M |
| Income Tax | 4.44M | 4.16M | 2.36M | 1.74M | 335.00K | -1.90M | 149.00K | 51.00K | 8.00K | -15.00K |
| Net Income | -204.71M | -96.03M | -222.61M | -94.59M | 15.57M | -34.38M | -24.75M | -122.61M | -73.03M | -83.45M |
| Net Income growth (YoY) | — | — | — | -707.70% | — | — | — | — | — | — |
| EPS (Basic) | -3.04 | -1.47 | -3.43 | -1.47 | 0.25 | -0.56 | -0.42 | -2.55 | -12.87 | -27.30 |
| EPS (Diluted) | -3.04 | -1.47 | -3.43 | -1.47 | 0.24 | -0.56 | -0.42 | -2.55 | -12.87 | -27.30 |
| Shares Outstanding (Basic) | 67.28M | 65.45M | 64.97M | 64.15M | 63.00M | 60.99M | 58.51M | 48.13M | 5.68M | 3.06M |
| Shares Outstanding (Diluted) | 67.28M | 65.45M | 64.97M | 64.15M | 64.35M | 60.99M | 58.51M | 48.13M | 5.68M | 3.06M |
| EBITDA | -169.59M | -82.52M | -217.51M | -78.52M | 36.50M | 2.49M | -10.65M | -38.81M | -56.08M | -72.56M |
| Gross Margin | 53.81% | 52.07% | 49.17% | 51.54% | 53.53% | 52.23% | 53.60% | 48.85% | 40.98% | 28.00% |
| Operating Margin | -18.45% | -10.54% | -31.19% | -11.59% | 3.22% | -1.60% | -4.62% | -24.27% | -58.50% | -92.64% |
| Net Margin | -20.17% | -10.21% | -29.77% | -11.81% | 2.21% | -6.89% | -6.83% | -66.68% | -67.87% | -99.05% |
This table shows 10 annual periods of Tandem Diabetes Care's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TNDM's reporting calendar. What is a income statement?